開能健康(300272.SZ):持股5%以上股東鈞天投資累計被動減持1%股份
格隆匯4月15日丨開能健康(300272.SZ)公佈,公司於2020年4月15日收到公司持股5%以上股東(原控股股東)鈞天(寧夏)投資管理中心(有限合夥)(“鈞天投資”)的《關於鈞天投資累計被動減持股份達到1%的告知函》,因協助司法執行,興業證券自2020年3月31日至2020年4月13日期間,興業證券通過集中競價的方式減持鈞天投資存放於興業證券信用擔保賬户的開能健康份股582.7929萬股,佔公司總股本的1%。
此次被動減持後,鈞天投資及其一致行動人合計持有股份8679.502萬股,佔總股本比例14.89%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.